RAP2A, member of RAS oncogene familyGenealiases: K-REV · KREV · RAP2 · RbBP-30
Q-omics provides the consensus-scored RAP2A profile across patient tissues and cancer cell-line models. RAP2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAP2A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RAP2A protein abundance shows 20,320 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where RAP2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAP2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAP2A survival associations across molecular data types. RAP2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAP2A RNA expression–survival associations across cancer types. High RAP2A expression shows unfavorable associations in ACC, LUSC and LIHC, but favorable associations in KIRC, LGG and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAP2A RNA expression.
This table summarizes RAP2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAP2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAP2A shows lower tumor expression in KICH and higher tumor expression in KIRC, COAD, LIHC, THCA and BLCA. The KIRC box plot shows higher RAP2A RNA expression in tumor versus normal tissue (log2 FC = +0.894, t-test p < 0.001).
This table shows molecular features associated with RAP2A in patient tissues and cancer cell lines. In patient samples, RAP2A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAP2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
